Abstract
Accumulating evidence indicates that low grade inflammation is closely associated with obesity-related disorders including type 2 diabetes, hypertension and atherosclerosis. Adiponectin is a fat-derived plasma protein with anti-inflammatory functions. Circulating levels of adiponectin are decreased in obese states, and these conditions are broadly associated with various obesity-related diseases. Furthermore, adiponectin has direct protective functions against cardiovascular disease, cerebrovascular disease, non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). In this review, we will focus on the protective functions of adiponectin against these obesity-related diseases from the view point of its anti-inflammatory properties.
Keywords: Adiponectin, cardiovascular disease, cerebrovascular disease, CKD, inflammation, insulin resistance, NASH.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Adiponectin as a Target in Obesity-related Inflammatory State
Volume: 15 Issue: 2
Author(s): Koji Ohashi, Daisuke Yuasa, Rei Shibata, Toyoaki Murohara and Noriyuki Ouchi
Affiliation:
Keywords: Adiponectin, cardiovascular disease, cerebrovascular disease, CKD, inflammation, insulin resistance, NASH.
Abstract: Accumulating evidence indicates that low grade inflammation is closely associated with obesity-related disorders including type 2 diabetes, hypertension and atherosclerosis. Adiponectin is a fat-derived plasma protein with anti-inflammatory functions. Circulating levels of adiponectin are decreased in obese states, and these conditions are broadly associated with various obesity-related diseases. Furthermore, adiponectin has direct protective functions against cardiovascular disease, cerebrovascular disease, non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). In this review, we will focus on the protective functions of adiponectin against these obesity-related diseases from the view point of its anti-inflammatory properties.
Export Options
About this article
Cite this article as:
Ohashi Koji, Yuasa Daisuke, Shibata Rei, Murohara Toyoaki and Ouchi Noriyuki, Adiponectin as a Target in Obesity-related Inflammatory State, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316122709
DOI https://dx.doi.org/10.2174/1871530315666150316122709 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery The Use of Thiazides in Chronic Kidney Disease
Current Hypertension Reviews Neonatal Persistent Pulmonary Hypertension Associated with Congenital Cystic Adenomatoid Malformation Treated with Sildenafil: Case Report
Current Pediatric Reviews Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model
Current Drug Delivery Prostaglandin E2: From Clinical Applications to Its Potential Role in Bone- Muscle Crosstalk and Myogenic Differentiation
Recent Patents on Biotechnology Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Executive Dyscontrol in Dementia, with Emphasis on Subcortical Pathology and the Role of Butyrylcholinesterase
Current Alzheimer Research Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Brain Perfusion In Sepsis
Current Vascular Pharmacology Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design Blood Pressure Control and Diabetic Retinopathy
Current Hypertension Reviews Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Editorial [Hot Topic: Modifying Coronary Risk Factors: C-Reactive Protein,Haemostatic Factors and Cardiovascular Risk (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Effect of a Dihydropyridine-Type Calcium Channel Blocker on Vascular Remodelling after Experimental Balloon Angioplasty
Cardiovascular & Hematological Agents in Medicinal Chemistry Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOC: Associations with Risk Factors
Current Radiopharmaceuticals